QI Biodesign

QI BIODESIGN was founded in 2021. The founding team includes Dr. Caixia Gao, who has world-class influence in the field of gene editing, Dr. Kevin Zhao, a student of renowned Harvard gene editing scientist David Liu (David R. Liu), and an R&D, operations, and commercialization team with extensive industry experience. The founding team is committed to building QI BIODESIGN into a hardcore high-tech enterprise with proprietary intellectual property rights, centered on next-generation gene editing technology. Currently, QI BIODESIGN is focused on developing novel gene editing technologies and exploring their applications in various fields such as bio-breeding, while actively establishing complementary collaborations with industry partners. The goal is to quickly develop products of social value, seize the commanding heights of gene editing technology, and contribute to China's effort to secure a leading position in the gene editing industry.